KR

Krish Ramadurai

Partner at AIX Ventures

San Francisco, California

Overview 

Krish Ramadurai is a Partner at AIX Ventures in San Francisco, California, with expertise in alternative investments and a focus on investing in DeepTech, BioTech, and other sectors. He has a diverse educational background with degrees from prestigious institutions like the University of Oxford, Harvard University, and Washington University in St. Louis. Ramadurai's career highlights include serving as a Venture Mentor at the National Venture Capital Association and holding various advisory and investor roles in companies like Nucleate, PreciPoint, and xCures, showcasing his strong analytical reasoning and financial acumen in the venture capital industry.

Work Experience 

AV

AIX Ventures

  • Partner

    2024 - Current

    Investing at the intersection of Healthcare, Life Sciences, and Artificial Intelligence: https://www.aixventures.com/

NV

National Venture Capital Association

  • Venture Mentor

    2023

National Venture Capital Association advocates for policies that promote long-term investment and encourage innovation.

nvca.org
N

Nucleate

  • Venture Advisor

    2021

    Nucleate is dedicated to empowering the next generation of biotech leaders who transform experiments into enterprises

a collaborative venture program enabling the formation of biotechnology companies addressing climate & sustainability challenges

nucleate.xyz
HU

Harvard University

  • Guest Lecturer

    2017

    Invited lecturer in the Faculty of Arts & Sciences for undergraduate and graduate Tissue Engineering for Clinical Applications and Biochemical Engineering & Synthetic Life courses with 25+ lectures given to date

P

PreciPoint

  • Chairman of the Board & Investor

    2023 - 2024

x

xCures

  • Board Observer & Investor

    2022 - 2024

xCures is an AI-based precision oncology platform that tightly integrates cancer research and care.

Raised $12,965,000.00 from HealthTech Capital.

xcures.com
S

Sorcero

  • Board Observer & Investor

    2022 - 2024

b

bit.bio

  • Investor

    2021 - 2024

AT

Attivare Therapeutics

  • Investor

    2021 - 2024

C

Caresyntax

  • Investor

    2021 - 2024

Caresyntax is a vendor neutral data-driven surgery platform that makes surgery smarter by reducing variability and improving efficency.

Raised $387,500,000.00 from PFM Health Sciences, Pictet Alternative Advisors, BlackRock Innovation Capital, MTIP AG, ProAssurance, Symbiotic Capital, Relyens, Vesalius Biocapital Partners, Aescuvest and Optum Ventures.

caresyntax.com

Education 

Articles About Krish

Relevant Websites